Lansforsakringar Fondforvaltning Ab (Publ) Vertex Pharmaceuticals Inc Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $8.19 Billion
- Q4 2024
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 144,708 shares of VRTX stock, worth $72.8 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
144,708Holding current value
$72.8 Million% of portfolio
0.71%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,764Shares Held
228MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$14.3 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.7 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$6.03 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.25 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $129B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...